Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$104.19 USD

104.19
1,818,035

+0.21 (0.20%)

Updated Oct 28, 2024 11:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (36 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer

by Zacks Equity Research

Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo

by Zacks Equity Research

Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as the Industry Recovers

by Kinjel Shah

Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.

Merck (MRK) Outperforms Industry This Year So Far: Here's Why

by Zacks Equity Research

Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.

Pfizer (PFE) Gets EUA for Use of Comirnaty Booster in Children

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.

Bristol Myers (BMY) Phase III CheckMate -901 Study Disappoints

by Zacks Equity Research

Bristol Myers (BMY) phase III CheckMate -901 study fails to meet the primary endpoint of overall survival in patients with untreated unresectable or metastatic urothelial cancer.

Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.

Mark Vickery headshot

Top Analyst Reports for Comcast, CME & Charter Communications

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), CME Group Inc. (CME), and Charter Communications, Inc. (CHTR).

Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.

Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.

    Why Merck (MRK) is a Top Value Stock for the Long-Term

    by Zacks Equity Research

    Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

    Mirati (MRTX) Q1 Loss Wider Than Expected, Sales Beat

    by Zacks Equity Research

    Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.

    Moderna (MRNA) Beats on Q1 Earnings, to Start Two Late Studies

    by Zacks Equity Research

    Moderna's (MRNA) Spikevax sales beat expectations. The company plans to start late-stage studies for Omicron-containing bivalent booster and seasonal flu vaccines later this year. Stock gains in pre-market.

    Is a Beat Likely for Moderna (MRNA) This Earnings Season?

    by Zacks Equity Research

    Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the first-quarter earnings call that can help it to reduce its dependence on Spikevax.

    AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.

    Seagen's (SGEN) Q1 Earnings & Revenues Surpass Estimates

    by Zacks Equity Research

    Seagen (SGEN) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates.

    Kinjel Shah headshot

    Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE

    by Kinjel Shah

    Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.

    Company News for Apr 29, 2022

    by Zacks Equity Research

    Companies In The News Are: TWTR, PYPL, MRK, MCD.

    Alkermes (ALKS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

    by Zacks Equity Research

    Alkermes (ALKS) rides high on both earnings and sales beating estimates in the first quarter of 2022.

    Merck (MRK) Q1 Earnings & Sales Beat, COVID Drug Adds $3.3B

    by Zacks Equity Research

    Merck (MRK) beats Q1 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.

    Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates

    by Zacks Equity Research

    Merck (MRK) delivered earnings and revenue surprises of 18.23% and 5.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More

    by Zacks Equity Research

    Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.

    Why Earnings Season Could Be Great for Merck (MRK)

    by Zacks Equity Research

    Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    The Zacks Analyst Blog Highlights Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan

    by Zacks Equity Research

    Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan have been included in this Analyst Blog.

    Mark Vickery headshot

    Top Research Reports for Novo Nordisk, AMD & Netflix

    by Mark Vickery

    Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Advanced Micro Devices, Inc. (AMD), and Netflix, Inc. (NFLX).